Author | Kenneth J. Bender, PharmD, MA


New Approaches Improve Diagnosis, Prediction of Type 2 Diabetes

July 26, 2019

One US researcher notes that using A1c alone to classify diabetes may misdiagnose >33 million Americans. What are the other options and how well do they work? Read on.

Novel Dual-mechanism Agent Acts on Diabetes, Metabolic Complications

June 25, 2019

ADA 2019 ICYMI: Tirzepatide, a GIP and GLP-1 receptor agonist, reduces A1c and BMI as well as biomarkers of metabolic dysfunction in type 2 diabetes patients. Four studies reviewed.

First Oral GLP-1 Agonist Showcased while Approval Pending

June 25, 2019

ADA 2019 ICYMI: Safety and efficacy of oral semaglutide in patients with T2DM was demonstrated in results of 3 PIONEER program clinical trials.  Highlights, here.

Linagliptin Found Safe in T2DM Patients at High Cardiorenal Risk

June 17, 2019

ADA 2019--Linagliptin, the DPP-4 inhibitor, showed similar risk for first or recurrent CV events or hopspitalization vs placebo in T2DM patients with high cardiorenal risk in CARMELINA subanalysis.

Fremanezumab is Next Migraine Preventive

September 13, 2018

Fremanezumab shown to be effective in treating acute and episodic migraine, according to a new presentation at PAINWeek 2018. 

Opioid Tapering Tips 1: Reducing Opioids without Withdrawal

September 11, 2018

News from PAINWeek 2018: "Tapering [opioids] is not detoxification," was one among many cautions and recommendations offered during several presentations in Las Vegas, Sept 4-8.

Opioid Tapering Tips 2: Lessening Withdrawal with Lofexidine

September 11, 2018

News from PAINWeek 2018: Lofexidine is found particularly suited to mitigate symptoms of rapid opioid withdrawal given its agonist activity at the 5-HT-1A serotonin receptor.

"Electroceuticals" Touted as Non-Opioid, Non-Drug Alternative for Pain

September 10, 2018

News from PAINWeek 2018: Electroceuticals could replace opioids in the treatment of chronic pain.

Reducing Risk and Rates of Severe Hypoglycemia

July 03, 2018

Severe hypoglycemia is more prevalent than previously believed and also significantly underreported. Details from 3 studies at ADA 2018.

Novel Markers, Glycemic Variability Predict CV Events in Diabetes

July 03, 2018

From ADA 2018: Two new biomarkers predict CV events independently of conventional risk factors, plus post-hoc analysis of VADT.